{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:57:26Z","timestamp":1769536646214,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272978"],"award-info":[{"award-number":["82272978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307100"],"award-info":[{"award-number":["22307100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577097"],"award-info":[{"award-number":["22577097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFA1303500"],"award-info":[{"award-number":["2022YFA1303500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Hepatitis C virus (HCV) still lacks a licensed vaccine. The envelope glycoprotein E2 is a key neutralizing target, but its dense N-glycan shield can hinder epitope exposure. In this study, we revisit E2 glycan editing and examine whether single-site deletion preserves antigen integrity while improving immune responses in mice under a DNA immunization setting. Using a secreted E2 ectodomain (sE2384\u2013661), we generated five N to D mutants at conserved sites (N1, N2, N4, N6, and N11) and evaluated them in a unified DNA immunization model with identical CpG content and delivery conditions across groups. The N2 mutant (N423, sE2-N2) maintained expression, secretion, and ER localization; furthermore, in mice, it was associated with higher anti-E2 titers and greater inhibition of H77 (genotype 1a) HCVcc at the tested dilutions, with limited activity against Con1 (1b). Cellular analyses showed increased IFN-\u03b3 ELISPOT counts and higher frequencies of granzyme B+\/perforin+ CD8+ T cells after N2 immunization, while IL-4 remained low. Functionally, N2 elicited stronger specific lysis of CT26-sE2 targets in vitro and slowed CT26-sE2 tumor growth in vivo. In HCV-infected ICR4R+ mice, therapeutic vaccination with sE2-N2 reduced blood HCV RNA and hepatic readouts compared with sE2. A monoclonal antibody isolated from sE2-N2-immunized mice (1C1) neutralized HCVcc in vitro and, after passive transfer, lowered viremia and liver signals in infected mice. Collectively, these findings indicate that selective removal of the N2 glycan preserves antigen properties and is associated with improved humoral and cellular immunity and measurable in vivo activity, supporting targeted glycan editing as a practical strategy to refine E2-based HCV vaccines.<\/jats:p>","DOI":"10.3390\/biom16020183","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:24:36Z","timestamp":1769423076000},"page":"183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Removal of HCV E2 N2 N-Glycan Is Associated with Improved Immune Responses in Mice"],"prefix":"10.3390","volume":"16","author":[{"given":"Yuan-Qin","family":"Min","sequence":"first","affiliation":[{"name":"Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China"},{"name":"State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430207, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Immunology, Binzhou Medical University, Yantai 264003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Dan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan 430071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-1344","authenticated-orcid":false,"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Hubei Province Key Laboratory of Allergy and Immunology, Department of Immunology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/cid\/ciaf334","article-title":"State-of-the-Art Review: Hepatitis C","volume":"81","author":"Bhattacharya","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","unstructured":"(2024). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Brunetto, M.R., and Bonino, F. (2025). The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals. Viruses, 17.","DOI":"10.3390\/v17030319"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41575-018-0026-5","article-title":"Management of acute HCV infection in the era of direct-acting antiviral therapy","volume":"15","author":"Martinello","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40618-022-01909-0","article-title":"Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity","volume":"46","author":"Rodia","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14278","DOI":"10.1128\/JVI.01911-14","article-title":"Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization","volume":"88","author":"Wong","year":"2014","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.32632","article-title":"Implementation of a controlled human infection model for evaluation of HCV vaccine candidates","volume":"77","author":"Barnes","year":"2023","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/gutjnl-2021-326323","article-title":"Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice","volume":"72","author":"Alzua","year":"2023","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2020.02.009","article-title":"IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses","volume":"73","author":"Han","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.immuni.2023.12.004","article-title":"Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection","volume":"57","author":"Frumento","year":"2024","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","article-title":"Structural insights into hepatitis C virus receptor binding and entry","volume":"598","author":"Kumar","year":"2021","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1128\/JVI.00459-07","article-title":"Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization","volume":"81","author":"Falkowska","year":"2007","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e0052322","DOI":"10.1128\/jvi.00523-22","article-title":"Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response","volume":"96","author":"Vijayamahantesh","year":"2022","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0300-9084(03)00004-X","article-title":"Glycosylation of hepatitis C virus envelope proteins","volume":"85","author":"Goffard","year":"2003","journal-title":"Biochimie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lavie, M., Hanoulle, X., and Dubuisson, J. (2018). Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00910"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12644","DOI":"10.1128\/JVI.01145-14","article-title":"Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins","volume":"88","author":"Bankwitz","year":"2014","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1073\/pnas.0501275102","article-title":"Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1","volume":"102","author":"Meunier","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41467-023-36183-y","article-title":"Regions of hepatitis C virus E2 required for membrane association","volume":"14","author":"Kumar","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.immuni.2024.03.001","article-title":"Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance","volume":"57","author":"Ogega","year":"2024","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","article-title":"HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design","volume":"24","author":"Flyak","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2018.11.003","article-title":"Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants","volume":"70","author":"Khera","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Martina, C.E., Crowe, J.E., and Meiler, J. (2023). Glycan masking in vaccine design: Targets, immunogens and applications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1126034"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41541-025-01161-6","article-title":"Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity","volume":"10","author":"Kulakova","year":"2025","journal-title":"NPJ Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00704-20","DOI":"10.1128\/JVI.00704-20","article-title":"Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization","volume":"94","author":"Pierce","year":"2020","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","article-title":"Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity","volume":"8","author":"Patra","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/jmv.25710","article-title":"Tree shrew bone marrow-derived mesenchymal stem cells express CD81, OCLN, and miR-122, facilitating the entire hepatitis C virus life cycle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, F., Hu, Y., Li, D., Chen, H., and Zhang, X.L. (2009). CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008142"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1128\/JVI.01548-10","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions","volume":"84","author":"Helle","year":"2010","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tzarum, N., Wilson, I.A., and Law, M. (2018). The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01315"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bhattarai, N., McLinden, J.H., Xiang, J., Kaufman, T.M., and Stapleton, J.T. (2015). Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005183"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coi.2017.03.014","article-title":"Antigen processing and presentation in the thymus: Implications for T cell repertoire selection","volume":"46","author":"Kondo","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41565-025-01877-5","article-title":"The pathways for nanoparticle transport across tumour endothelium","volume":"20","author":"Wu","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.accounts.3c00151","article-title":"Ligand Chemistry in Antitumor Theranostic Nanoparticles","volume":"56","author":"Lin","year":"2023","journal-title":"Acc. Chem. Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/2\/183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:15:33Z","timestamp":1769490933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/2\/183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["biom16020183"],"URL":"https:\/\/doi.org\/10.3390\/biom16020183","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}